<DOC>
	<DOCNO>NCT02135640</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics , pharmacodynamics denosumab administer subcutaneously healthy adult China .</brief_summary>
	<brief_title>China HVT Safety , PK , PD</brief_title>
	<detailed_description>Denosumab fully human monoclonal IgG2 antibody RANKL investigate therapeutic agent bone diseases characterize excessive bone resorption , primary secondary osteoporosis , metastatic bone disease , disease involve bone loss associate increase osteoclast function . This single-blind , placebo-controlled single-dose study . All subject randomize denosuamb 60 mg , denosumab 120 mg placebo ration 3:3:2 . The purpose study evaluate safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) denosumab administer subcutaneously healthy adult China . The primary endpoint safety : subject incidence treatment-emergent adverse event , include clinically significant change physical examination , laboratory safety test , ECG vital sign . The secondary endpoint PK PD ( s-CTX1 ) parameter estimate .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Resident China Chinese ancestry . AST , ALT , alkaline phosphatase bilirubin â‰¤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male female 18 65 year age , inclusive , date birth , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea . In questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory . OR Childbearing potential agrees use one contraception method list Section 8.1 appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception duration study minimum 6 month last dose study medication . Body weight least 50 kg body mass index ( BMI ) 19 24 kg/m2 time screen . Capable give write informed consent , include compliance requirement restriction list consent form . Average QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . A prior history current evidence osteomyelitis ONJ . An active dental jaw condition require oral surgery . A planned invasive dental procedure course study . A nonhealed dental oral surgery . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A positive test HIV antibody . A positive test syphilis Screening . Abnormal serum calcium : current hypocalcemia hypercalcemia . Albuminadjusted serum calcium level must within normal range central laboratory . History regular alcohol consumption within 6 month study define average weekly intake &gt; 14 drinks/week men &gt; 7 drinks/week woman . One drink equivalent ( 12 g alcohol ) = 150 ml ( 5 ounce ) table wine 360 ml ( 12 ounce ) beer 45 ml ( 1.5 ounce ) 80 proof distil spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . History sensitivity study medication , especially know sensitivity mammalianderived drug preparation , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive serum human chorionic gonadotropin ( hCG ) test screen urine hCG test prior dose ( day 1 ) . A chest Xray compute tomography ( CT ) scan reveals evidence clinical significant abnormality e.g. , tuberculosis . A chest Xray must take Day1 chest Xray CT scan available within 6 month prior day . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History sensitivity heparin heparininduced thrombocytopenia . Significant change physical activity 6 month study drug administration constant level intense physical exercise . Prior use medication within 4 week 5 halflives ( whichever period great ) study . This include medication , limited : Estrogencontaining contraceptive Bisphosphonates Fluoride Hormone replacement therapy ( i.e. , tibolone , estrogen , estrogenlike compound raloxifene ) Calcitonin Strontium Parathyroid hormone derivative Supplemental vitamin D ( &gt; 1000 IU/day ) Glucocorticosteroids ( inhaled topical corticosteroid administer 2 week prior enrolment allow ) Anabolic steroid Calcitriol Diuretics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>